WASHINGTON, D.C. (August 12, 2021) — AAM and our member companies are ready to partner with the Biden administration to ensure all Americans have access to the lifesaving medications they need at a price that they can afford. Ninety percent of the prescriptions filled in the United States are for safe, effective and affordable generic medications, yet they account for only 20% of all drug spending. President Biden rightly recognizes the centrality of generic drugs to the American health care system and sees the incredible potential for biosimilars to play a similarly essential role in the coming years. We look forward to working with the Administration to increase the $313 billion in savings that generic drugs generated in 2019 and build on the tremendous success of biosimilars in recent years.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.